ArticleJournal of Alzheimer's disease : JAD2015
Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
Article in Journal of Alzheimer's disease : JAD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer's Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial.Journal of Alzheimer's disease : JAD · 2018Trial
- A cross-cohort comparison of the prevalence and clinical significance of Alzheimer's disease biomarkers in people with versus without HIV.Journal of neurovirology · 2026Article
- The Syn-sleep trial protocol: detection of cutaneous phosphorylated alpha-synuclein in REM sleep behavior disorder.Biomarkers in medicine · 2026Article
- The small HDL particle hypothesis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Preliminary proteomic analysis of human tears in lacrimal adenoid cystic carcinoma and pleomorphic adenoma.International journal of ophthalmology · 2023Article
- Passage of exogeneous fine particles from the lung into the brain in humans and animals.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Alpha desynchronization during Stroop test unmasks cognitively healthy individuals with abnormal CSF Amyloid/Tau.Neurobiology of aging · 2022Article
- Blood-brain barrier link to human cognitive impairment and Alzheimer's Disease.Nature cardiovascular research · 2022Article
- Stronger implicit interference in cognitively healthy older participants with higher risk of Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use.Journal of personalized medicine · 2020Review
- Article
- A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.Journal of Alzheimer's disease : JAD · 2020Article
- Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.Nature medicine · 2019Article
- Fine Particulate Matter Exposure and Cerebrospinal Fluid Markers of Vascular Injury.Journal of Alzheimer's disease : JAD · 2019Article
- Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid.Journal of Alzheimer's disease : JAD · 2019Article
- Review
- Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.Molecular neurobiology · 2018Article
- Article
- Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.JAMA neurology · 2017Article
- Genome-wide association and interaction studies of CSF T-tau/AβNeurobiology of aging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMeso Scale Discovery (MSD) recently established electrochemiluminescence-based assays to measure cerebrospinal fluid (CSF) levels of total tau (t-tau) and amyloid-β 1-42 peptide (Aβ42) that can aid in the diagnosis of Alzheimer's disease (AD). The goal of this investigation is to independently evaluate this platform and establish cut-off values of these biomarkers for AD diagnosis.
objectiveTo validate the analytical and clinical performance of the MSD t-tau and Aβ42 kits and propose diagnostic cut-off values for the field.
methodsThe analytical performance of the CSF t-tau and Aβ42 assays was determined, followed by assessment of diagnostic performance of CSF t-tau, Aβ42, and t-tau/Aβ42 in three clinically characterized cohorts.
resultsBoth MSD assays demonstrated consistent and stable analytical performance, as well as resistance to several important pre-analytic variables. Diagnostically, t-tau/Aβ42 performed the best.
conclusionsOur results independently confirm the analytical and clinical performance of the MSD CSF t-tau and Aβ42 assays. Based on a large, multi-center, clinically-diagnosed cohort, we propose for the first time candidate diagnostic cut-offs for MSD measured CSF t-tau, Aβ42, and t-tau/Aβ42. However, these values needs to be refined as more subjects are included and the assays are tested by other laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.